JP2022513566A5 - - Google Patents

Info

Publication number
JP2022513566A5
JP2022513566A5 JP2021517866A JP2021517866A JP2022513566A5 JP 2022513566 A5 JP2022513566 A5 JP 2022513566A5 JP 2021517866 A JP2021517866 A JP 2021517866A JP 2021517866 A JP2021517866 A JP 2021517866A JP 2022513566 A5 JP2022513566 A5 JP 2022513566A5
Authority
JP
Japan
Application number
JP2021517866A
Other languages
Japanese (ja)
Other versions
JP7578587B2 (ja
JP2022513566A (ja
JPWO2020074894A5 (https=
Filing date
Publication date
Priority claimed from GB1816447.5A external-priority patent/GB2578093B/en
Application filed filed Critical
Publication of JP2022513566A publication Critical patent/JP2022513566A/ja
Publication of JP2022513566A5 publication Critical patent/JP2022513566A5/ja
Publication of JPWO2020074894A5 publication Critical patent/JPWO2020074894A5/ja
Priority to JP2024091837A priority Critical patent/JP7836853B2/ja
Application granted granted Critical
Publication of JP7578587B2 publication Critical patent/JP7578587B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021517866A 2018-10-09 2019-10-09 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物 Active JP7578587B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091837A JP7836853B2 (ja) 2018-10-09 2024-06-05 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816447.5 2018-10-09
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091837A Division JP7836853B2 (ja) 2018-10-09 2024-06-05 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Publications (4)

Publication Number Publication Date
JP2022513566A JP2022513566A (ja) 2022-02-09
JP2022513566A5 true JP2022513566A5 (https=) 2022-10-11
JPWO2020074894A5 JPWO2020074894A5 (https=) 2022-10-11
JP7578587B2 JP7578587B2 (ja) 2024-11-06

Family

ID=64394831

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517866A Active JP7578587B2 (ja) 2018-10-09 2019-10-09 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物
JP2024091837A Active JP7836853B2 (ja) 2018-10-09 2024-06-05 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091837A Active JP7836853B2 (ja) 2018-10-09 2024-06-05 Hfa-134a中のrpl554を含む吸入による投与用医薬組成物

Country Status (27)

Country Link
US (2) US20210379053A1 (https=)
EP (2) EP3820446B1 (https=)
JP (2) JP7578587B2 (https=)
KR (1) KR20210073532A (https=)
CN (1) CN112912064B (https=)
AU (1) AU2019358585B2 (https=)
BR (1) BR112021006712A2 (https=)
CA (1) CA3113167A1 (https=)
CY (1) CY1124943T1 (https=)
DK (1) DK3820446T3 (https=)
ES (1) ES2899744T3 (https=)
GB (1) GB2578093B (https=)
HR (1) HRP20220053T1 (https=)
HU (1) HUE057780T2 (https=)
IL (1) IL282032B1 (https=)
LT (1) LT3820446T (https=)
MX (2) MX2021003599A (https=)
MY (1) MY207302A (https=)
PH (1) PH12021550767A1 (https=)
PL (1) PL3820446T3 (https=)
PT (1) PT3820446T (https=)
RS (1) RS62775B1 (https=)
SG (1) SG11202102567UA (https=)
SI (1) SI3820446T1 (https=)
SM (1) SMT202200044T1 (https=)
WO (1) WO2020074894A1 (https=)
ZA (1) ZA202102039B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3142701T3 (en) 2014-05-12 2018-08-13 Verona Pharma Plc New treatment
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB201916915D0 (en) 2019-11-20 2020-01-01 Amr Centre Ltd Compounds
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024088364A1 (zh) * 2022-10-28 2024-05-02 江苏恒瑞医药股份有限公司 一种包含异喹啉酮类化合物的药物组合物及其制备方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208310T3 (es) 1999-03-31 2004-06-16 Vernalis Limited Derivados de pirimido(6,1-a) isoquinolin-4-ona.
PH12013500261A1 (en) * 2010-08-09 2013-03-04 Verona Pharma Plc Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
EP2819645A2 (en) * 2012-02-28 2015-01-07 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
EP2968313B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
DK3142701T3 (en) * 2014-05-12 2018-08-13 Verona Pharma Plc New treatment
CN110051627A (zh) * 2014-09-15 2019-07-26 维罗纳制药公司 包含rpl554的液体吸入制剂
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Similar Documents

Publication Publication Date Title
BR112021022807A2 (https=)
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
JP2022513566A5 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021017728A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)
BR112021017083A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)